ADVA
5.5.2020 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has transported 400Gbit/s over its existing long-haul network using the ADVA FSP 3000 TeraFlex™ . The trials pave the way for ultra-fast access to Finland’s supercomputers and could offer a major boost to Europe’s research and education community. They also demonstrated the terminal’s ability to carry 1200Gbit/s channels for the transport of 3x 400GbE over a live meshed ROADM infrastructure. What’s more, the trials highlighted how TeraFlex™ maximizes spectral efficiency in any open line system. Using the terminal’s ultra-flexible modulation and adaptive baud rate capabilities, FUNET also achieved new levels of bandwidth efficiency – and therefore could significantly reduce opex – for 400GbE, 100GbE and lower-speed services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005036/en/
“These trials demonstrate how the ADVA FSP 3000 TeraFlex™ performs over long-haul distances, and the results were well above our expectations. It was the first time when we really needed a gridless line system to enable a full choice of line speeds and modulations. The powerful performance of TeraFlex™ and its flexibility to tune line speed and modulation, will allow us to optimize spectrum usage and minimize the cost of providing services to our users,” said Jani Myyry, FUNET network, CSC – IT Center for Science. “Our network provides essential connectivity for research and education institutes in Finland and throughout the Nordics. Initially we were aiming for transport based on 100Gbit/s and 200Gbit/s but are now seeing an increasing need for speeds above that, up to use cases requiring a bandwidth of multiple Tbit/s. TeraFlex and our ADVA open line system infrastructure enable us to efficiently scale our network with line speeds of 400Gbit/s and above. The trials show how TeraFlex™ dramatically increases flexibility and efficiency for 100GbE and 400GbE transport over long-haul distances.”
FUNET’s tests underline the ability of the ADVA FSP 3000 TeraFlex™ to massively increase the capacity of existing terrestrial long-haul networks. The low-power 1RU terminal enables channels of up to 1200Gbit/s for 3x 400GbE services and a total capacity of 3.6Tbit/s. Using network telemetry, software-defined fractional QAM modulation and adaptive baud rate capabilities, the solution is able to ensure maximum spectral efficiency at every point in the network. This enables operators to leverage previously unused optical spectrum so that deployed infrastructure can be made to transport far more data. As well as succeeding with 600Gbit/s transport over 278km and with 400Gbit/s over 2,844km, the trials showed the power of harnessing granular increments with speeds of 300Gbit/s over 4,681km.
“These tests show how it’s now possible to optimize all optical paths over any reach. They demonstrate to the research and education industry that there’s a new way for long-distance networks to support soaring data demand. With its ultra-flexible modulation, our compact and open FSP 3000 TeraFlex™ is the key to unlocking maximum value in any network,” commented Henning Hinderthür, VP, product line management, ADVA. “Together with the CSC – IT Center for Science, we’ve shown how deployed infrastructure operating with coherent channels can transport traffic at unprecedented speeds. And not only that. Our unique TeraFlex™ solution also enhances performance, improves port efficiency and delivers major opex savings. It massively increases the efficiency of existing 100GbE connectivity, while also providing a way to meet the needs of emerging data-hungry applications for 400GbE and beyond.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005036/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
